Table 1.
DMB administered after permanent coronary artery ligation mitigates adverse LV remodeling and improves cardiac function.
| 14 days post-MI | 28 days post-MI | ||||
|---|---|---|---|---|---|
| Vehicle n = 6 | DMB n = 7 | Vehicle n = 6 | DMB n = 7 | ||
| HR | bpm | 432 ± 32.2 | 467 ± 50.1 | 446 ± 22.7 | 478 ± 37.3 |
| EF | % | 39.6 ± 4.5 | 49.0 ± 5.9* | 32.9 ± 5.5 | 42.3 ± 5.3* |
| FS | % | 19.3 ± 2.4 | 24.7 ± 3.5* | 15.6 ± 2.8 | 21.0 ± 3.1* |
| LV Vol,d | uL | 113.4 ± 39.7 | 96.9 ± 23.3 | 110.4 ± 38.5 | 125.0 ± 22.1 |
| LV Vol,s | uL | 69.3 ± 27.4 | 49.9 ± 14.0 | 75.4 ± 31.3 | 71.8 ± 12.8 |
| LVID,d | mm | 4.85 ± 0.73 | 4.56 ± 0.51 | 4.8 ± 0.7 | 5.1 ± 0.4 |
| LVID,s | mm | 3.93 ± 0.66 | 3.44 ± 0.46 | 4.1 ± 0.7 | 4.0 ± 0.3 |
| LVPW,d | mm | 1.04 ± 0.26 | 1.25 ± 0.31 | 1.2 ± 0.3 | 1.7 ± 0.3* |
| LVPW,s | mm | 1.21 ± 0.24 | 1.48 ± 0.31 | 1.6 ± 0.4 | 2.1 ± 0.2* |
| Est. scar size | % | 34.3 ± 3.0 | 28.8 ± 7.1 | 34.5 ± 6.8 | 30.3 ± 7.1 |
Data are presented as mean ± standard deviation. HR, Heart rate; EF, Ejection Fraction; FS, Fractional Shortening; DMB, 2-Quinoxalinamine, 6,7-dichloro-N-(1,1-dimethylethyl)-3-(methylsulfonyl)-, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline; LV Vol,d, Left Ventricle End-Diastolic Volume; LV Vol,s, LV End- Systolic Volume; LVID,d, LV Internal Diameter, Diastole; LVID,s, LV Internal Diameter, systole; LVPW,d, LV Posterior Wall thickness, diastole; LVPW,s, LV Posterior Wall thickness, systole. Naïve EF % 60.4 ± 6.7, FS % 29.3 ± 6.3 (n = 19). *p < 0.05 vs vehicle.